TransCode shareholders approve preferred stock conversion, stock plan increase, and director elections

Transcode Therapeutics, Inc.

Approved conversion of Series A, B, and C preferred stock into common stock for Nasdaq listing compliance.
Stockholders approved amendment to 2021 Stock Option Plan increasing available shares by 1,734,262.
Elected six directors: Philippe P. Calais, Elizabeth Czerepak, Thomas A. Fitzgerald, Erik Manting, Magda Marquet, Jack E. Stover.
Ratified WithumSmith+Brown, PC as independent auditor for FY 2026 with 393,497 votes for.
Nasdaq approved the Company's initial listing application in connection with Proposals 1 and 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.